Mr David Tamblyn

Mr David Tamblyn
 Position AHTA Manager
 Org Unit Adelaide Health Technology Assessment
 Email david.tamblyn@adelaide.edu.au
 Telephone +61 8 8313 0608
 Location Floor/Room Level Four ,  44-60 Rundle Mall - Rundle Mall Plaza ,   North Terrace
  • Biography/ Background

    Mr Tamblyn has more than 10 years' experience in the critical appraisal of evidence for health technology assessment across a broad range of services. He is involved in the evaluation of submissions for devices and pharmaceutical to the TGA for regulatory purposes, the evaluation of submissions for pharmaceuticals to the Pharmaceutical Benefits Advisory Committee, and the evaluation of medical services submitted to the Medical Benefits Advisory Committee. Mr Tamblyn supports and manages staff performing such assessments and provides quality assurance of deliverables.

    Regulatory assessments of Devices

    Evaluation of the safety and performance of devices (including application audits and conformity assessments) for the Therapeutic Goods Administration. Evaluations involve the synthesis of pre-clinical data, clinical data, published studies, registry and post market surveillance data, risk management plans and activities, and the audit of product information or similar documents provided to health care practitioners and patients. Common indications for devices assessed are: orthopaedics, ophthalmology, cardiology, interventional radiology, pain management.

    Regulatory assessments of Oncology Drugs

    Evaluation of the safety, efficacy and pharmacology of new oncology drugs for the Therapeutic Goods Administration for regulatory purposes. Evaluations involve the assessment of the quality of the clinical evidence (Module 5) of a pharmaceutical, which is synthesised into a benefit / risk profile, and a recommendation to the ACM and/or TGA delegate.

    Assessments of pharmaceuticals for reimbursement

    Evaluation of the safety, effectiveness and cost-effectiveness of pharmaceuticals across a range of clinical areas for the Pharmaceutical Benefits Advisory Committee (PBAC) for the purposes of establishing suitability for reimbursement on the PBS. Evaluations involve the assessment of clinical and economic evidence, and of the financial impact to the Australian health care system.

    Assessments of medical services for reimbursement

    Evaluation of the safety, effectiveness and cost-effectiveness of medical services, including co-dependent testing, molecular and genetic testing, imaging, programs and therapeutic procedures, for the Medical Services Advisory Committee (MSAC) for the purposes of establishing suitability for reimbursement on the MBS. Evaluations involve the assessment of clinical and economic evidence, and of the financial impact to the Australian health care system.

    Additional expertise

    Mr Tamblyn has been involved in a range of projects relating to HTA, including broader reviews and development of methodology. These projects include:

    • Co-lead researcher for "Guidelines for preparing assessments for the Medical Services Advisory Committee, Version 1.0, May 2021"
    • Co-lead researcher for "Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee, Version 5.0, September 2016"
    • Review of an Australian lung cancer screening program
    • Guidance for the evaluation of tumour type agnostic therapies
    • Review of a class of devices for the TGA
    • Review of the Life Saving Drugs Programme
    • Review of MBS Items for specific ophthalmology services under the MBS Quality Framework
    • Review of the Statins Therapeutic Group
    • Vertebroplasy / Kyphoplasty for the treatment of vertebral compression fracture
    • Brachytherapy for the treatment of prostate cancer
    • National Evidence Based Guidelines for the Prevention, Identification and Management of Foot Complications in Diabetes

    Teaching

    Mr Tamblyn has contributed to teaching in the School of Public Health and the School of Medicine in epidemiology and health economics.

  • Qualifications

    University Qualifications:

    Master of Public Health, University of Adelaide (2011)

    Bachelor of Health Science, University of Adelaide (2001)

    Courses:

    University Teaching for Effective Student Learning, University of Adelaide, 2014

    MAEFA courses: Quantitative Analysis using Stata 13, Working Efficiently with Stata 13, Programming with Stata 13, Raw Data Management with Stata 13

    TreeAge Pro Training: Cost-effectiveness models, Markov models and Micro-simulation

    Survival Analysis short course (Monash)

    Modelling Methods for Health Economic Evaluations (University of York, McMaster University collaboration)

    Introduction to Network Meta-analysis / Mixed treatment comparisons (CADTH)

  • Publications

    Peer reviewed publications

    Leach, Damien A., Eleanor F. Need, Roxanne Toivanen, Andrew P. Trotta, Helen M. Palenthorpe, David J. Tamblyn, Tina Kopsaftis et al. "Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome." Oncotarget (2015).

    Merlin, Tracy, David Tamblyn, and Benjamin Ellery. "What's in a name? Developing definitions for common health technology assessment product types of the international network of agencies for health technology assessment (INAHTA)." International journal of technology assessment in health care (2014): 1-8.

    Tamblyn, DJ, Chopra, S, Yu, C, Kattan, MW, Pinnock, C & Kopsaftis, T 2011, 'Comparative analysis of three risk assessment tools in Australian patients with prostate cancer', BJU International, vol. 108, pp. 51-56.

    Beckmann, K, Pinnock, CB, Tamblyn, DJ, Kopsaftis, T, Stapleton, AMF & Roder, DM 2009, 'Clinical and socio-demographic profile of an Australian multi-institutional prostate cancer cohort', Asia-Pacific Journal of Clinical Oncology, vol. 5, no. 4, pp. 247-256.

    Stapleton, AM, Johns, RL, Kopsaftis, T, Tamblyn, DJ & Pinnock, CB 2008, 'Abnormal PSA tests--delays in referral', Aust Fam Physician, vol. 37, no. 1-2, Jan-Feb, pp. 84-88.


    Selected contracted reports

    Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee, Version 5.0. September 2016. Commonwealth of Australia, Canberra, ACT.

    Tamblyn, DJ, Ellery, B & Merlin, T 2011, Brachytherapy for the treatment of prostate cancer. MSAC Application 1089.1, Review of Interim Funded Service, Commonwealth of Australia, Canberra, ACT.

    Doidge, J, Merlin, T, Liufu, Z, Tamblyn, DJ, Jia, LY & Hiller, JE 2011, Review of interim funded service: Vertebroplasty and new review of Kyphoplasty. MSAC Application 27.1, Commonwealth of Australia, Canberra, ACT.

    Morona, JK, Newton, S, Wang, S, Tamblyn, DJ, Ellery, B & Merlin, T 2014, Genetic testing for hereditary mutations in the VHL gene that cause von Hippel-Lindau syndrome. MSAC Application 1153, Assessment Report., Commonwealth of Australia, Canberra, ACT.

    Merlin, T, Street, J, Holton, C, Mundy, L, Tamblyn, DJ, Ellery, B, Juneja, V, Reddin, E, Scrimgeour, S & Hennessy, S 2011, Review of MBS Items for specific ophthalmology services under the MBS Quality Framework., Commonwealth of Australia, Canberra, ACT.

  • Professional Associations

    Deputy Editor, International Journal of Technology Assessment in Health Care https://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care

    Committee Member, South Australian Policy Advisory Committee on Technology (SAPACT)

    Committee Member, South Australian Medicines Evaluation Panel (SAMEP)

    Working Group Member, TGA Expert Working Group for Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) 

    Agency Member, International Network of Agencies for Health Technology Assessment (INAHTA)

    Individual Member, Health Technology Assessment International (HTAi)

The information in this directory is provided to support the academic, administrative and business activities of the University of Adelaide. To facilitate these activities, entries in the University Phone Directory are not limited to University employees. The use of information provided here for any other purpose, including the sending of unsolicited commercial material via email or any other electronic format, is strictly prohibited. The University reserves the right to recover all costs incurred in the event of breach of this policy.

Entry last updated: Saturday, 21 May 2022

To link to this page, please use the following URL:  https://www.adelaide.edu.au/directory/david.tamblyn